A Promising Small Molecule for Vanishing White Matter Disease
Investigators from Calico Life Sciences LLC and AbbVie report the effects of a novel drug targeting the genetic basis of Vanishing White Matter Disease (VWMD).
Saved in:
Main Authors: | Divakar S Mithal (Author), Jennifer P Rubin (Author) |
---|---|
Format: | Book |
Published: |
Pediatric Neurology Briefs Publishers,
2018-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adult-onset vanishing white matter disease presenting as dementia
by: Soreya Belarbi, et al.
Published: (2021) -
A Novel Mutation in the EIF2B4 Gene Associated with Leukoencephalopathy with Vanishing White Matter
by: D. Hettiaracchchi, et al.
Published: (2018) -
EIF2B2 gene mutation causing early onset vanishing white matter disease: a case report
by: Ilaria Filareto, et al.
Published: (2022) -
Stilbenes: a promising small molecule modulator for epigenetic regulation in human diseases
by: Jing Tian, et al.
Published: (2023) -
Closed Gastroschisis with Vanished Small Bowel and Jejunal Atresia
by: R S Sisodiya, et al.
Published: (2020)